Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Galdakao, Spain Clinical Trials

A listing of Galdakao, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

A Double-blind Study to Investigate Efficacy Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical diagnosis of diabetic kidney disease. BAY1142524 or placebo ...

Phase

0.0 miles

Learn More »

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

Lung cancer has been the most common carcinoma in the world for several decades. Non-small cell lung carcinoma (NSCLC) represents approximately 80-85% of all lung cancers. At the time of diagnosis approximately 70% of NSCLC patients already have advanced or metastatic disease not amenable to surgical resection. A significant percentage ...

Phase

5.04 miles

Learn More »

Platelet-Rich Plasma in Acute Muscle Injuries

STUDY DESIGN: Randomized Clinical Trial. METHODS 41 football players are included in the study. It is used randomly PRP injection or a homeopathic product in muscle injuries (hamstrings or quadriceps), in the early stage (first 48-72 hours). One week later, the investigators do a second infiltration with the same product, ...

Phase

5.04 miles

Learn More »

Stimulation of the Efferent Loop Before Loop Ileostomy Closure

Stimulation was performed 3 weeks prior to the ileostomy closure using 500 cc of a thickening substance (saline and nutritional thickener) through the efferent limb.

Phase

6.04 miles

Learn More »

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

This is a multi-center exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti-PDL1 drug. 110 patients will be enrolled in this trial to examine the efficacy and outcomes of ...

Phase

6.98 miles

Learn More »

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

This is a phase 2 study to evaluate safety and efficacy of ABBV-105 and ABBV-599 (ABBV-105 plus upadacitinib) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid Arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs(bDMARD)-inadequate response ...

Phase

6.98 miles

Learn More »

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Nave patients 18 years of age with histological confirmation of locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with an activating EGFR mutation and concomitant T790M mutation. Evidence of measurable or evaluable metastatic disease is required. Primary objective: To evaluate the efficacy of osimertinib (AZD9291), in terms of ...

Phase

8.3 miles

Learn More »

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

This Bridging Extension is to determine if intravenous CD101 is safe [Day 45- 52 for subjects with candidemia only, or Day 52- 59 for subjects with invasive candidiasis with or without candidemia] and effective [Day 14 ( 1 day)] in the treatment of candidemia and/or invasive candidiasis when compared to ...

Phase

8.3 miles

Learn More »

GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial. Eligible patients will receive injections of Diamyd/placebo into an inguinal lymph gland at three occasions, with one month intervals in combination with an oral vitamin D/placebo regimen (starting 1 month ahead of injections) during 4 months. All patients will ...

Phase

8.3 miles

Learn More »

NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents

Hypothesis NK cells are the natural defence against cancer cells. Thus, supplementing compatible NK cells from a related donor might increase the probability to eliminate any residual chemotherapy resistant cell in Acute myelogenous leukemia patients. Description NK cells will be donated from a compatible family member who has a certain ...

Phase

8.3 miles

Learn More »